Hem › Levercancer (hepatocellulärt karcinom) › Tennessee
Kliniska studier för Levercancer (hepatocellulärt karcinom) i Tennessee
14 studier för Levercancer (hepatocellulärt karcinom) söker deltagare vid platser i Tennessee.
Städer i Tennessee
Officiell studietext (engelska)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- SCRI Oncology Partners, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #3, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT05176483A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT07291076A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Scri Oncology Partners, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 16 sep. 2026 · NCT06427941Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
RekryterarFas 1/2
12 Months – 30 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 17 aug. 2026 · NCT05919264A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 5 aug. 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
RekryterarFas 2
Ålder 8 och äldre · Alla kön · Uppdaterad 27 juli 2026 · NCT05503797Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- St. Jude Children's Research Hospital, Memphis
RekryterarFas 1/2
Upp till ålder 30 · Alla kön · Uppdaterad 19 maj 2026 · NCT05468359Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- The West Clinic, Germantown
- University of Tennessee Medical Center, Knoxville
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 apr. 2026 · NCT05733598Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- HCA Research Institute, LLC, Brentwood
RekryterarFas 1
Ålder 18 till 65 · Alla kön · Uppdaterad 16 mars 2026 · NCT07176650A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 136, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 21 nov. 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
- University of Tennessee Medical Center, Knoxville
Rekryterar
Ålder 18 och äldre · Alla kön · Uppdaterad 27 sep. 2018 · NCT03686709Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.